Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19.
暂无分享,去创建一个
T. Choueiri | M. Galsky | N. Nock | Gregory Riely | Douglas B. Johnson | Y. Shyr | E. Ruíz-García | L. Fecher | E. Wulff-Burchfield | D. Kwon | V. Koshkin | T. Wise-Draper | D. Bowles | Y. Rao | C. Hwang | A. Desai | O. Eton | R. Jandarov | R. McKay | T. Halfdanarson | D. Provenzano | M. Bilen | M. Thompson | Shaheer Khan | Saif Alimohamed | Shilpa Gupta | L. Tachiki | T. Rhodes | A. Schoenfeld | F. Moria | S. Gulati | S. Berg | Z. Bakouny | A. Schmidt | C. Labaki | M. Wotman | Zhuoer Xie | M. Tucker | D. Shah | A. Kulkarni | M. Puc | M. Joshi | C. Jani | M. Gatti-Mays | N. Knox | A. Nizam | P. Grover | A. Elkrief | S. Shah | L. Pomerantz | D. Gopalakrishnan | A. J. Portuguese | J. Shaya | D. Flora | J. Panasci | B. Hayes-Lattin | S. Matar | B. Bashir | H. Khan | M. Glover | Cecilia A. Castellano | Taylor K Nonato | Chih-Yuan Hsu | J. Warner | E. Hsu | S. Mishra | Andrea V. Rivera | Gary K. Schwartz | J. Awosika | L. Weissmann | S. Subbiah | Alicia Gesenhues | M. Hendawi | Jacob J Ripp | Melissa Valdez-Reyes | Yuanchu J Yang | Sumit A. Shah | Y. Yang | Sumit A Shah | Taylor K. Nonato | Saif I. Alimohamed | Cecilia Castellano | A. Portuguese
[1] C. Chute,et al. Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative , 2021, The Lancet Rheumatology.
[2] A. Ribas,et al. At the Crossroads: COVID-19 and Immune-Checkpoint Blockade for Cancer , 2021, Cancer Immunology Research.
[3] C. June,et al. Cytokine Storm , 2020, The New England journal of medicine.
[4] Omar H. Butt,et al. A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance , 2020, Cancer Cell.
[5] J. Warner,et al. COVID-19 and Cancer: Current Challenges and Perspectives , 2020, Cancer Cell.
[6] E. Robilotti,et al. Determinants of COVID-19 disease severity in patients with cancer , 2020, Nature Medicine.
[7] Zhiquan Hu,et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study , 2020, The Lancet Oncology.
[8] D. Kerr,et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study , 2020, The Lancet.
[9] M. Santillana,et al. Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak , 2020, Cancer discovery.
[10] Xiaohu Zheng,et al. Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients , 2020, National science review.
[11] Bo Diao,et al. Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19) , 2020, Frontiers in Immunology.
[12] Paul A. Harris,et al. The REDCap consortium: Building an international community of software platform partners , 2019, J. Biomed. Informatics.
[13] Heshu Sulaiman Rahman,et al. DRAFTING A MANUSCRIPT , 2017 .